Enable job alerts via email!
A leading diagnostics firm in the UK is seeking a Reagent Development Scientist to develop innovative temperature-stable reagents for molecular diagnostics. This hands-on role involves collaboration with various teams to design, optimise, and validate reagents. Candidates should have a PhD in molecular biology and significant lab experience. The company offers a dynamic work environment and a robust benefits package, including private medical insurance and generous holidays.
Social network you want to login/join with:
At LEX Diagnostics, we’re reinventing PCR for the real world. Our point-of-care system, LEX VELO, delivers ultra-fast molecular diagnostics, and your reagents are at the heart of it.
We’re looking for a Reagent Development Scientist to help develop temperature-stable, lyophilised reagents that perform under pressure, literally and figuratively. You’ll be helping us push PCR beyond the lab and into hospitals, clinics, and emergency settings around the world.
This is a hands on role, perfect for a scientist who thrives in the lab, enjoys complex problem solving, and wants to help build next generation diagnostics in a fast paced, collaborative environment.
What you’ll be doing
This isn’t just lab work, it’s working side by side with biologists, engineers, and production teams to ensure our reagents are robust, reliable, and ready for the real world. You’ll:
Requirements
What we’re looking for
Nice to have
We offer a collaborative and ambitious culture, alongside a fantastic benefits package:
Who are we and what’s ahead for you?
LEX Diagnostics was founded in 2020. Our innovative system integrates effortlessly into primary care settings, bringing PCR-level sensitivity to urgent care centres, physician offices, labs, and pharmacies, all at a significantly lower cost per test than other molecular platforms.
2025 is a milestone year: we’ve just submitted dual 510(k) and CLIA waiver applications to the U.S. FDA. We are hopeful for approval. That means you’ll be joining just as we gear up for a major product launch a moment that will have a direct, meaningful impact on your future career.
What’s next for LEX?
In December 2023, QuidelOrtho invested in LEX Diagnostics, including an exclusive option to acquire the company following FDA clearance. This strategic partnership means:
We are hopeful for FDA clearance in late 2025 or early 2026, and this will mean transitioning from a nimble start-up, to a globally supported diagnostics leader. Our plans are to do this without losing the curiosity, creativity, and drive that got us here.
Because here, your science really matters. You’ll work on visible, vital problems that directly impact diagnostic accuracy, speed, and usability. You’ll be part of a collaborative, cross-functional team that values deep technical expertise and shared progress. And you’ll help shape how reagents power the future of point-of-care testing.
Let your science take centre stage, and help us build the future of diagnostics.